Ghiadoni L, Taddei S, Virdis A, Sudano I, Di Legge V, Meola M, Di Venanzio L, Salvetti A
These are promising results, but the studys authors note that more research is needed, and clinicians must also consider potential adverse effects, evaluate the cost-effectiveness of these medications for each patient, and closely monitor for any improvement or worsening of eating disorders and related side effects. That hesitation is shared by the National Eating Disorder Association (NEDA), who published an opinion paper on GLP-1s and eating disorders in 2024, stating: While there is some evidence that GLP-1s can decrease the number of binge eating episodes for those with BED, little is known about the long term physical and psychological impact on those with eating disorders. How GLP-1s could also fuel eating disorders The same mechanisms that make these medications helpful for some could make them harmful for others
Blue Dart & Delhivery
Additionally, individuals who are currently taking medications that interact with Semaglutide GLP-1, such as insulin or other medications that lower blood sugar should consult their healthcare provider before using Semaglutide GLP-1
In parallel with its ongoing engagement with the FDA, Aardvark intends to unblind the clinical data accumulated to date across the HERO trial to assess the totality of available efficacy and safety data and to support an informed determination of next steps for the ARD-101 program
